| Code | CSB-RA006163MB15HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Tazlestobart, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive T-cell responses. Dysregulation of CTLA4-mediated immune suppression is implicated in various conditions, including autoimmune diseases and cancer, where tumor cells exploit this pathway to evade immune surveillance.
Tazlestobart represents a therapeutic antibody developed to modulate CTLA4 activity, with potential applications in oncology and immune-related disorders. This biosimilar provides researchers with a cost-effective tool for investigating CTLA4 biology, immune checkpoint mechanisms, and T-cell regulation in preclinical models. It enables studies exploring immune modulation strategies, tumor immunology, autoimmunity research, and the development of combination immunotherapy approaches.
There are currently no reviews for this product.